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Acute myeloid leukemia (AML) still has a rather poor prognosis, which is mainly ascribed to relapse in the majority of patients despite achievement of complete remission (CR). To prevent relapse, minimal residual disease (MRD) remaining in CR has to be completely eradicated. The graft-versus-leukemia effect induced by allogeneic hematopoietic stem cell transplantation is the most powerful mechanism for eradication of MRD, thus strongly suggesting the therapeutic potential of immunotherapy.
The Wilms' tumor gene WT1 is highly expressed in various types of malignancies, and the WT1 protein is one of the most promising leukemia and tumor-associated antigens. 1 --6 Based on findings of pre-clinical studies, we performed a phase I clinical study of WT1 peptide immunotherapy for patients with AML, myelodysplastic syndromes, breast or lung cancer, and were able to confirm the safety and clinical efficacy of this therapy. 7 In this report, we describe the long-term outcome for AML patients enrolled in this study.
The major inclusion criteria for vaccination were that patients had HLA-A*2402 and that WT1 mRNA levels, which reflect the amount of MRD, 8, 9 were 41 Â 10 3 or 41 Â 10 2 copies/mg RNA in bone marrow (BM) or peripheral blood (PB), respectively. A natural WT1 peptide (amino acid 235 --243 CMTWNQMNL) or the modified WT1 peptide (CYTWNQMNL) 10 emulsified with Montanide ISA51 adjuvant (Freund Corporation, Tokyo, Japan) was i.d. injected, and the vaccination was performed three times at 2-week intervals. The terms of both clinical and molecular responses were clearly defined as respectively, a decrease in leukemic blast cells in BM and a decrease in WT1 mRNA levels in BM and/or PB. Molecular CR was defined as undetectable levels of WT1 mRNA in PB (o50 copies/mg RNA). Molecular relapse was defined as abnormal levels of WT1 mRNA (X50 copies/mg RNA in PB and/or X1000 copies/mg RNA in BM). Vaccination was extended for patients who showed clinical response or no progression within 2 weeks from the end of three WT1 vaccinations. As for immunological monitering, WT1 tetramer þ CD8 þ T cells and IFN-g þ WT1 tetramer þ CD8 þ T cells were analyzed. Of the eight AML patients with hematological CR (leukemic blast o5%) but with MRD who were WT1-vaccinated, five patients who showed a decrease in WT1 mRNA levels (molecular response) were repeatedly WT1-vaccinated, but two relapsed later. The remaining three patients received WT1 vaccine for X8 years and have survived in molecular CR for X8 years without significant adverse effects except for local erythema at the vaccine injection sites (Table 1 ). . As his disease was considered to be at a high risk of hematological relapse, WT1 vaccination with 3 mg of natural WT1 peptide was begun in February 2003. WT1 mRNA levels in BM decreased to normal levels during administration of three WT1 vaccinations (time point (1)) but increased to abnormal levels after discontinuation of the vaccination (time point (2)). WT1 vaccination was therefore started again, and again WT1 mRNA levels decreased to normal levels (time point (3)). These findings demonstrated that WT1 vaccination was effective for eradication of MRD. As WT1 mRNA levels increased after the second discontinuation of WT1 vaccination, the vaccination was initiated once more in June 2003 (time point (4)). The vaccine was changed from a natural to a modified WT1 peptide in September 2004 (Year 1.7) because a phase I/II clinical study of WT1 immunotherapy using a modified WT1 peptide for solid tumors showed the evidence of the modified WT1 peptides' effectiveness. WT1 mRNA levels decreased to normal levels (o50 copies/mgRNA in PB) B4 years after the start of WT1 vaccination and have been maintained at normal levels until now, although WT1 mRNA levels remained at abnormal levels during the first 4 years. The WT1 vaccination was continued until February 2011, but stopped at that time point owing to patient's request with our agreement.
CASE REPORTS
Case 2 A 49-year-old woman was diagnosed as AML (M1) in June 2000. Leukemic blast cells were characterized by CD34 þ CD56 þ . The patient achieved molecular CR (WT1 mRNA: o50 copies/mg RNA in PB) after the second induction chemotherapy followed by a multicourse consolidation and maintenance therapy. After molecular CR had been maintained for 2.5 years, however, BM examination showed molecular relapse with 4.5 Â (Figure 1c ). As her disease was considered to be at a high risk of hematological relapse, WT1 vaccination with 3 mg of modified WT1 peptide was initiated in April 2004. WT1 mRNA levels in PB gradually decreased from 880 copies/mg RNA before WT1 vaccination and reached undetectable levels (o50 copies/mg RNA) 6.5 years after the vaccination. Cells with t(6;11)(q21;q23) had also remained undetectable. WT1 vaccination was continued until February 2011, but stopped at that time point owing to the patient's request with our agreement.
In all three cases reported here, frequencies of WT1 tetramer þ CD8 þ T cells that were already high before WT1 vaccination compared with those in healthy donors (HDs) transiently increased further after the vaccination and then decreased, but remained at higher levels during the vaccination. It should be noted that IFN-g þ WT1 tetramer þ CD8 þ T cells, which are considered to be functionally active, were not detected before WT1 vaccination, but appeared after the vaccination had been initiated and stayed at clearly detectable levels during the vaccination. In case 3, the increase to 0.19% in the frequency of WT1 tetramer þ CD8 þ T cells including higher frequencies of IFN-g þ CD8 þ T cells in PB around year 6 paralleled the decrease in WT1 mRNA to undetectable levels.
DISCUSSION
In the three AML who have been treated with WT1 peptide vaccine for X8 years, WT1 mRNA levels that reflect the amount of MRD have remained at undetectable levels, suggesting that the vaccination may have resulted in a cure for these patients. On the basis of WT1 mRNA levels, MRD before WT1 vaccination was 
estimated at B10
10 cells, which may be equivalent to B1.0% leukemic blast cells in BM. The presence of such high levels of MRD in these patients suggested that clinical relapse was impending. 8, 9 Conventionally, cure-oriented therapy for such patients comprises only allogeneic hematopoietic stem cell transplantation. As shown by these cases, WT1 immunotherapy may be the first choice of treatment for AML patients who have MRD after induction chemotherapy but cannot tolerate allogeneic hematopoietic stem cell transplantation. The findings of this study suggest that WT1 peptide vaccination merits consideration as an alternative cure-oriented therapy for AML patients showing hematological CR but also MRD, and are at a high risk of clinical relapse. Frequency of WT1 tetramer þ CD8 þ T cells in the three AML patients was already elevated before WT1 vaccination compared with that usually observed in HDs (o0.08%). These findings indicate that the immune system of these AML patients responded to the endogenous WT1 protein derived from leukemic cells.
þ T cells, were not detected before WT1 vaccination, but appeared after WT1 vaccination in all three patients and remained at clearly detectable levels throughout the vaccination. The appearance and continuing presence of these IFN-g þ WT1 tetramer þ CD8 þ T cells are likely contributors to the eradication of MRD, thus resulting in molecular CR. Furthermore, it was shown that, upon stimulation with WT1 peptide, a fraction of WT1 tetramer þ CD8 þ T cells expressed a CD107 antigen that appeared on surface of CTLs in direct association with secretion of cytotoxic granules that contained perforin and granzyme 11 (data not shown), strongly indicating the potential cytotoxicity of WT1 tetramer þ CD8 þ T cells and the relevance of their frequency analysis during the clinical courses.
In conclusion, long-term WT1 peptide vaccination for X8 years was found to be safe and effective for the eradication of MRD and WT1 immunotherapy merits consideration as a promising cureoriented therapy for AML patients with MRD who are at high risk of relapse.
